- Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertension
- Biochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and portal hypertension
- Hepatic Expression of Galectin-3, a Pro-fibrotic and Pro-inflammatory Marker
- Clinical utility of the ELF score in compensated NASH cirrhotic patients with portal hypertension
- Histological correlation with portal pressures and varices in NASH cirrhosis using quantitative digital pathology
“For the sake of our patients, we need to bring more attention to liver cirrhosis and, particularly, to portal hypertension, a clinically relevant complication of the disease for which no etiologic treatment exists,” said
Abstracts will be available for viewing by attendees on the AASLD website and are also featured in the October supplement to the AASLD journal, Hepatology.
Presentation Details
Title: Prevalence of esophageal and gastric varices in patients with compensated non-alcoholic steatohepatitis (NASH) cirrhosis and portal hypertension. Data from the NAVIGATE study
Abstract Number: 2329
Authors: Boudes Pol, Alkhouri Naim,
Date:
Time:
Title: Biochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and clinically suspected portal hypertension: an ongoing prospective cohort
Abstract Number: 2337
Authors: Boudes P, Alkhouri N, Elgouhari H, Lucas K, Lawitz E, Borg B, Vuppalanchi R, Behari J, Patel C, Noureddin M, Reiss G, Halegoua-De Marzio D, Caldwell S, Ghalib R, Landaverde C, Patel P, Shiffman M, Moore A, Kopaczewski J,
Date:
Time:
Title: Hepatic Expression of Galectin-3, a Pro-fibrotic and Pro-inflammatory Marker –
Publication Number: 1407
Authors:
Date:
Time:
Title: Clinical utility of the ELF score in compensated NASH cirrhotic patients with portal hypertension
Publication Number: 2319
Authors: Boudes PF, Lowe E,
Date:
Time:
Title: Histological correlation with portal pressures and varices in NASH cirrhosis using quantitative digital pathology
Publication Number: 36696
Authors:
Date: Available as ePoster
About Belapectin
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. A Phase 2 study showed belapectin may prevent the development of esophageal varices in NASH cirrhosis, and these results provide the basis for the conduct of the NAVIGATE trial. The NAVIGATE trial (www.NAVIGATEnash.com), titled “A Seamless Adaptive Phase 2b/3, Double-Blind, Randomized, Placebo-controlled Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (
About the American Association for the Study of Liver Diseases (AASLD)
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients. It also advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies. AASLD’s annual scientific conference, The Liver Meeting™, is the world’s premier meeting on liver disease, bringing together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology.
About
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies as modified to meet the requirements of the FDA may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. Global factors such as coronavirus may continue to impact NASH patient populations around the globe and slow trial enrollment and prolong the duration of the trial and significantly impact associated costs. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended
Company Contact:
(678) 620-3186
ir@galectintherapeutics.com
Source:
Source:
2022 GlobeNewswire, Inc., source